MobileODT, an Israeli FemTech startup focusing on AI-powered cervical screening, has caught the eye of the US National Cancer Institute (NCI), with the NCI awarding Mobile ODT with a $2.3 million grant. The Small Business Innovation Research Authority grant is given by the NCI to companies that are technologically and clinically reducing the suffering from cancer.
“We are honored to receive such a prestigious grant, especially from National Cancer Institute. It’s a recognition of the value that our technology is bringing to women’s health,” said Leon Boston, MobileODT CEO.
The Israeli startup has developed a novel cervical cancer screening technology, utilizing complex machine learning and AI algorithms. The company’s technology offers an alternative screening modality to the current standard-of-care with significantly improved accuracy. It allows for a broader range of physicians, to perform cervical cancer screening in real-time, providing a more efficient method of diagnosis in comparison to the long list of follow-ups method.